Transcriptional Regulation of Fibroblast Growth Factor 21 Expression

Kwi-Hyun Bae

Jung-Guk Kim

Keun-Gyu Park

Abstract

INTRODUCTION

The fibroblast growth factor 21 (FGF21) family includes 22 members that are divided into seven subfamilies based on phylogeny and sequence [1,2]. Most FGF family members bind to FGF receptors on the cell surface and require heparin sulfate to stabilize the binding [3]. While classic FGFs act through an autocrine or paracrine mechanism to regulate cell growth and differentiation, FGF19 subfamily members including FGF15/19, FGF21, and FGF23 lack heparin-binding properties and can; therefore, be released into the circulation to act as endocrine factors [4]. In place of heparin, the transmembrane protein Klotho is required for FGF19 subfamily members to activate FGF receptors [5]; α-Klotho serves as a coreceptor for FGF23, while β-Klotho serves as a coreceptor for FGF15/19 and FGF21 [6,7,8,9].

FGF21 is a metabolic regulator that has favorable metabolic effects on glucose and lipid metabolism [10,11,12]. As mentioned above, interaction with β-Klotho is an essential step in FGF21-receptor complex activation. β-Klotho is almost exclusively expressed in the liver, adipose tissue, and pancreas [5], which may explain why these specific tissues are the predominant site of FGF21 action, although almost all tissues express FGF receptors [13]. FGF21 has attracted attention since Kharitonenkov et al. [10] discovered its potent insulin-sensitizing actions through increased glucose uptake in rodents. It is particularly important to distinguish between the systemic pharmacological effects of FGF21 during obesity and comorbid conditions and the tissue-specific effects of FGF21 that occur under more physiological conditions (Fig. 1). The physiological actions of FGF21 occur at lower concentrations and in more restricted organ systems and tissues than the pharmacological actions [14]. In fasting, FGF21 expression is induced by peroxisome proliferator-activated receptor α (PPARα) in the liver [15,16] and acts through endocrine mechanisms for adaptive starvation responses including gluconeogenesis, ketogenesis, torpor, and inhibition of somatic growth [12,14,17]. In the fed state, FGF21 expression is induced by PPARγ in white adipose tissue and acts in an autocrine or paracrine fashion to increase PPARγ activity [14,18,19,20]. As a consequence, during feeding, the induction of FGF21 in white adipose tissue fails to increase circulating levels of FGF21 [21]. Pharmacological administration of FGF21 affects multiple organs and tissues including the pancreas, adipose tissue, liver, and the central nervous system [14]. Systemic administration of FGF21 increases insulin sensitivity and energy expenditure, causing a loss of body weight and improvements in glucose and lipid metabolism in obese rodents and primates [10,11,22]. Furthermore, several reports have also shown that administration of FGF21 results in a significant decrease in lipid accumulation in the liver of diet-induced obese mice [22], suggesting that FGF21 could be a promising drug candidate for treatment of metabolic syndrome, with benefits for many of the symptoms of this disease.

FGF21 AND DIABETES MELLITUS

Serum FGF21 levels and hepatic FGF21 expression increase during obesity or type 2 diabetes [23]. However, although endogenous FGF21 fails to improve glucose and lipid metabolism during obesity [24], pharmacological administration of FGF21 improves not only insulin sensitivity but also β-cell function, which contributes to the beneficial glycemic actions of FGF21 [25]. FGF21 treatment increases islet cell number and insulin staining in db/db mice, demonstrating the ability of FGF21 to preserve β-cell mass and function [25]. Several lines of evidence suggest that FGF21 protects pancreatic β-cells by reducing β-cell glucolipotoxicity and directly reducing β-cell apoptosis via the Akt pathway [25,26,27]. As progressive β-cell loss is important for the pathophysiology of type 2 diabetes, these data suggest that FGF21 could be used to prevent the progression of type 2 diabetes.

TRANSCRIPTIONAL REGULATION OF FGF21 VIA UPREGULATION OF PPARα OR PPARγ

In 2007, three groups found that fasting induces hepatic FGF21 expression and that PPARα is required for this normal starvation response [15,16,28]. PPARα, a nuclear receptor highly expressed in liver, binds directly to the FGF21 gene promoter to induce its transcription [16]. PPARα activation promotes fatty acid oxidation, ketogenesis, and gluconeogenesis [12,29]. PPARα knockout mice accumulate hepatic triglycerides and become hypoketonemic and hypoglycemic during fasting [30]. Hepatocytes are the primary source of circulating FGF21, and its synthesis is driven by the action of PPARα [16]. PPARγ is a nuclear receptor that regulates many genes involved in adipocyte differentiation, lipid synthesis and storage, insulin signaling, and glucose metabolism [31,32]. Activation of PPARγ also increases the secretion of adipokines implicated in whole-body insulin sensitization [33]. Recent studies demonstrated that PPARγ activation increases FGF21 production in adipose tissue, the secondary source of FGF21, which then acts as an autocrine or endocrine factor to improve insulin action [21,34].

REGULATION OF FGF21 EXPRESSION BY OTHER TRANSCRIPTION FACTORS

In addition to PPARα and PPARγ, several studies have suggested that other transcription factors are involved in the regulation of hepatic FGF21 expression. Adams et al. [35]. report that thyroid hormone receptor β, which mediates the action of tri-iodothyronine in the liver, stimulates lipolysis, and hepatic fatty acid oxidation via FGF21 induction. The beneficial metabolic effects of all-trans retinoic acid (RA), which is mediated by RA receptor β (RARβ) binding, are similar to those induced by FGF21, including body weight loss and improvements in glucose and lipid metabolism [36,37]. Several researchers have speculated that FGF21 expression might be regulated by RARβ. FGF21 was characterized as a novel target gene of RARβ in hepatocytes, and hepatic RARβ can bind to putative RA responsive elements in the FGF21 promoter in a fasting-induced manner [38]. RA receptor-related orphan receptor α (RORα) is a nuclear receptor that plays a critical role in lipid metabolism [39], possibly by modulation of FGF21 secretion [40]. A recent study demonstrated that RORα directly regulates the expression and secretion of FGF21 [40]. Cyclic AMP response element-binding protein H (CREBH), an endoplasmic reticulum membrane-bound transcription factor, also induces hepatic FGF21 expression [41,42]. CREBH-deficient mice exhibit impaired fasting-induced expression of FGF21 [43]. Furthermore, CREBH is induced by fenofibrate, which is a well-known PPARα activator. We reported that CREBH mediates fenofibrate-induced suppression of hepatic lipogenesis [44]. Nur77, also known as nuclear receptor subfamily 4 group A member 1 (NR4A1), is a transcription factor in the Nur nuclear hormone receptor superfamily [45]. Nur77 expression is highly induced in adipose tissue, skeletal muscle, and liver by diverse stimuli including β-adrenergic agonists, cold exposure, and fatty acids [46,47,48,49,50,51]. Hepatic Nur77 expression is potently induced by glucagon secretion and fasting, and Nur77 is implicated in hepatic gluconeogenesis [52]. Recently, we found that during fasting, Nur77 mediates hepatic FGF21 expression and that alpha lipoic acid (ALA) increases hepatic FGF21 expression via upregulation of Nur77 (unpublished data).

REGULATION OF FGF21 TRANSCRIPTION BY THERAPEUTIC AGENTS

Increased serum FGF21 concentrations are associated with obesity and insulin resistance in rodents that respond poorly to endogenous FGF21, indicating that metabolic syndrome could be the result of an FGF21-resistant state [22,24]. However, pharmacological administration of FGF21 improves glucose and lipid metabolism in diabetic rhesus monkeys, which present with the same characteristics as diabetic humans [11]. Therefore, regulators of FGF21 transcription, especially in obesity, may be potential drug targets useful for reducing FGF21 resistance. Fenofibrate, a PPARα agonist, is used clinically for the treatment of hypertriglyceridemia [53] and increases FGF21 expression via PPARα activation [54]. As mentioned previously, FGF21 is a downstream target of PPARγ, and the therapeutic effects of PPARα agonists may be mediated by stimulation of hepatic FGF21 production [16]. Thiazolidinediones, a class of antidiabetic drugs (insulin sensitizers), are well-known PPARγ agonists, and FGF21 expression can be regulated by PPARγ agonists in adipose tissue [55]. Cotreatment with FGF21 and a PPARγ agonist results in synergistic adipocyte differentiation and glucose uptake in adipose tissue [19]. Moreover, thiazolidinedione increases FGF21-induced tyrosine phosphorylation of the FGF receptor and induces β-Klotho expression [56,57]. ALA, a naturally occurring thiol antioxidant, is an essential cofactor for mitochondrial respiration [58] and is often used to manage diabetic complications [59,60]. ALA mediates a diverse range of activities including regulation of glucose and lipid metabolism by modulation of PPAR-regulated genes and key enzymes [61]. We previously demonstrated that ALA activates adenosine monophosphate-activated protein kinase and reduces lipid accumulation in livers of rodents fed a high-fat diet [62]. We also reported that ALA enhances Nur77 expression in vascular cells [63] suggesting that ALA treatment may induce nutritionally regulated gene expression in the liver through the upregulation of fasting-induced transcription factors. Recently, we found that ALA increases hepatic FGF21 expression via upregulation of Nur77 and CREBH (unpublished data). Despite many studies on FGF21, its mechanism of action remains controversial and is not fully understood. It is now clear that the FGF21 transcription factor pathway is one of the most promising drug targets for the treatment of metabolic syndrome. Therefore, further studies focused on the transcriptional regulation of FGF21 are necessary.

CONCLUSIONS

FGF21 has emerged as an important hormonal regulator of glucose and lipid metabolism and a promising agent for the treatment of obesity and type 2 diabetes. Therefore, it is necessary to understand the mechanisms responsible for FGF21 expression and identify other transcription factors including nuclear receptors which are able to regulate hepatic FGF21 expression.

Fig. 1

Endocrine, autocrine, and pharmacological actions of fibroblast growth factor 21 (FGF21) and its transcription factors. Fasting induces FGF21 expression in the liver through several transcription factors, and FGF21 acts as an endocrine hormone to induce ketogenesis, gluconeogenesis, fatty acid oxidation, and torpor and to inhibit somatic growth. In the fed state, FGF21 expression in white adipose tissue is induced by peroxisome proliferator-activated receptor gamma (PPARγ), and FGF21 acts through an autocrine or paracrine mechanism to increase PPARγ activity. Pharmacological administration of recombinant FGF21 (rFGF21) affects multiple tissues and has beneficial effects on lipid and glucose metabolism in metabolic disease, including obesity and diabetes mellitus. Recent studies have demonstrated that several metabolically-active drugs produce hepatic FGF21, suggesting a relationship between their actions in glucose and lipid metabolism with the up-regulation of FGF21 production. CREBH, cyclic adenosine monophosphate (AMP) response element-binding protein H; RARβ, retinoic acid (RA) receptor β; RORα, RA receptor-related orphan receptor α; Nur77, nerve growth factor IB; TRβ, thyroid hormone receptor β; T2DM, type 2 diabetes mellitus.

Footnotes

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by grants from the National Research Foundation of Korea (no. 2012R1A2A2A01043867) funded by the Ministry of Science, ICT & Future Planning.

References

1. ItohNOrnitzDMEvolution of the Fgf and Fgfr gene familiesTrends Genet200420563569[PubMed][Google Scholar]
2. McKeehanWLWangFKanMThe heparan sulfate-fibroblast growth factor family: diversity of structure and functionProg Nucleic Acid Res Mol Biol199859135176[PubMed][Google Scholar]
3. GalzieZKinsellaARSmithJAFibroblast growth factors and their receptorsBiochem Cell Biol199775669685[PubMed][Google Scholar]
4. DostalovaIHaluzikovaDHaluzikMFibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitusPhysiol Res20095817[PubMed][Google Scholar]
5. SuzukiMUeharaYMotomura-MatsuzakaKOkiJKoyamaYKimuraMAsadaMKomi-KuramochiAOkaSImamuraTbetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3cMol Endocrinol20082210061014[PubMed][Google Scholar]
6. KurosuHOgawaYMiyoshiMYamamotoMNandiARosenblattKPBaumMGSchiaviSHuMCMoeOWKuro-oMRegulation of fibroblast growth factor-23 signaling by klothoJ Biol Chem200628161206123[PubMed][Google Scholar]
7. KurosuHChoiMOgawaYDicksonASGoetzREliseenkovaAVMohammadiMRosenblattKPKliewerSAKuro-oMTissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21J Biol Chem20072822668726695[PubMed][Google Scholar]
8. WuXGeHGupteJWeiszmannJShimamotoGStevensJHawkinsNLemonBShenWXuJVeniantMMLiYSLindbergRChenJLTianHLiYCo-receptor requirements for fibroblast growth factor-19 signalingJ Biol Chem20072822906929072[PubMed][Google Scholar]
9. UrakawaIYamazakiYShimadaTIijimaKHasegawaHOkawaKFujitaTFukumotoSYamashitaTKlotho converts canonical FGF receptor into a specific receptor for FGF23Nature2006444770774[PubMed][Google Scholar]
10. KharitonenkovAShiyanovaTLKoesterAFordAMMicanovicRGalbreathEJSanduskyGEHammondLJMoyersJSOwensRAGromadaJBrozinickJTHawkinsEDWroblewskiVJLiDSMehrbodFJaskunasSRShanafeltABFGF-21 as a novel metabolic regulatorJ Clin Invest200511516271635[PubMed][Google Scholar]
11. KharitonenkovAWroblewskiVJKoesterAChenYFClutingerCKTignoXTHansenBCShanafeltABEtgenGJThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21Endocrinology2007148774781[PubMed][Google Scholar]
12. InagakiTLinVYGoetzRMohammadiMMangelsdorfDJKliewerSAInhibition of growth hormone signaling by the fasting-induced hormone FGF21Cell Metab200887783[PubMed][Google Scholar]
13. AdamsACYangCCoskunTChengCCGimenoRELuoYKharitonenkovAThe breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissueMol Metab201223137[PubMed][Google Scholar]
14. PotthoffMJKliewerSAMangelsdorfDJEndocrine fibroblast growth factors 15/19 and 21: from feast to famineGenes Dev201226312324[PubMed][Google Scholar]
15. BadmanMKPissiosPKennedyARKoukosGFlierJSMaratos-FlierEHepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic statesCell Metab20075426437[PubMed][Google Scholar]
16. InagakiTDutchakPZhaoGDingXGautronLParameswaraVLiYGoetzRMohammadiMEsserVElmquistJKGerardRDBurgessSCHammerREMangelsdorfDJKliewerSAEndocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21Cell Metab20075415425[PubMed][Google Scholar]
17. ZhangJKaasikKBlackburnMRLeeCCConstant darkness is a circadian metabolic signal in mammalsNature2006439340343[PubMed][Google Scholar]
18. MaLRobinsonLNTowleHCChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liverJ Biol Chem20062812872128730[PubMed][Google Scholar]
19. MuiseESAzzolinaBKuoDWEl-SherbeiniMTanYYuanXMuJThompsonJRBergerJPWongKKAdipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic statesMol Pharmacol200874403412[PubMed][Google Scholar]
20. WangHQiangLFarmerSRIdentification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytesMol Cell Biol200828188200[PubMed][Google Scholar]
21. DutchakPAKatafuchiTBookoutALChoiJHYuRTMangelsdorfDJKliewerSAFibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinedionesCell2012148556567[PubMed][Google Scholar]
22. CoskunTBinaHASchneiderMADunbarJDHuCCChenYMollerDEKharitonenkovAFibroblast growth factor 21 corrects obesity in miceEndocrinology200814960186027[PubMed][Google Scholar]
23. ZhangXYeungDCKarpisekMStejskalDZhouZGLiuFWongRLChowWSTsoAWLamKSXuASerum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humansDiabetes20085712461253[PubMed][Google Scholar]
24. FisherFMChuiPCAntonellisPJBinaHAKharitonenkovAFlierJSMaratos-FlierEObesity is a fibroblast growth factor 21 (FGF21)-resistant stateDiabetes20105927812789[PubMed][Google Scholar]
25. WenteWEfanovAMBrennerMKharitonenkovAKosterASanduskyGESewingSTreiniesIZitzerHGromadaJFibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathwaysDiabetes20065524702478[PubMed][Google Scholar]
26. WooYCXuAWangYLamKSFibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectivesClin Endocrinol (Oxf)201378489496[PubMed][Google Scholar]
27. KliewerSAMangelsdorfDJFibroblast growth factor 21: from pharmacology to physiologyAm J Clin Nutr201091254S257S[PubMed][Google Scholar]
28. LundasenTHuntMCNilssonLMSanyalSAngelinBAlexsonSERudlingMPPARalpha is a key regulator of hepatic FGF21Biochem Biophys Res Commun2007360437440[PubMed][Google Scholar]
29. KerstenSSeydouxJPetersJMGonzalezFJDesvergneBWahliWPeroxisome proliferator-activated receptor alpha mediates the adaptive response to fastingJ Clin Invest199910314891498[PubMed][Google Scholar]
30. HashimotoTCookWSQiCYeldandiAVReddyJKRaoMSDefect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fastingJ Biol Chem20002752891828928[PubMed][Google Scholar]
31. FajasLDebrilMBAuwerxJPPAR gamma: an essential role in metabolic controlNutr Metab Cardiovasc Dis2001116469[PubMed][Google Scholar]
32. LehrkeMLazarMAThe many faces of PPARgammaCell2005123993999[PubMed][Google Scholar]
33. NawrockiARRajalaMWTomasEPajvaniUBSahaAKTrumbauerMEPangZChenASRudermanNBChenHRossettiLSchererPEMice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonistsJ Biol Chem200628126542660[PubMed][Google Scholar]
34. DrakulicBJJuranicIOEricSZlohMRole of complexes formation between drugs and penetration enhancers in transdermal deliveryInt J Pharm20083634049[PubMed][Google Scholar]
35. AdamsACAstapovaIFisherFMBadmanMKKurganskyKEFlierJSHollenbergANMaratos-FlierEThyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent mannerJ Biol Chem20102851407814082[PubMed][Google Scholar]
36. BerryDCDeSantisDSoltanianHCronigerCMNoyNRetinoic acid upregulates preadipocyte genes to block adipogenesis and suppress diet-induced obesityDiabetes20126111121121[PubMed][Google Scholar]
37. TsuchiyaHIkedaYEbataYKojimaCKatsumaRTsuruyamaTSakabeTShomoriKKomedaNOshiroSOkamotoHTakuboKHamaSShudoKKogureKShiotaGRetinoids ameliorate insulin resistance in a leptin-dependent manner in miceHepatology20125613191330[PubMed][Google Scholar]
38. LiYWongKWalshKGaoBZangMRetinoic acid receptor beta stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in miceJ Biol Chem20132881049010504[PubMed][Google Scholar]
39. HamiltonBAFrankelWNKerrebrockAWHawkinsTLFitzHughWKusumiKRussellLBMuellerKLvan BerkelVBirrenBWKruglyakLLanderESDisruption of the nuclear hormone receptor RORalpha in staggerer miceNature1996379736739[PubMed][Google Scholar]
40. WangYSoltLABurrisTPRegulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor alphaJ Biol Chem20102851566815673[PubMed][Google Scholar]
41. ChinKTZhouHJWongCMLeeJMChanCPQiangBQYuanJGNgIOJinDYThe liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinomaNucleic Acids Res20053318591873[PubMed][Google Scholar]
42. OmoriYImaiJWatanabeMKomatsuTSuzukiYKataokaKWatanabeSTanigamiASuganoSCREB-H: a novel mammalian transcription factor belonging to the CREB/ATF family and functioning via the box-B element with a liver-specific expressionNucleic Acids Res20012921542162[PubMed][Google Scholar]
43. LeeJHGiannikopoulosPDuncanSAWangJJohansenCTBrownJDPlutzkyJHegeleRAGlimcherLHLeeAHThe transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolismNat Med201117812815[PubMed][Google Scholar]
44. MinAKJeongJYGoYChoiYKKimYDLeeIKParkKGcAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesisDiabetologia201356412422[PubMed][Google Scholar]
45. ChangCKokontisJLiaoSSChangYIsolation and characterization of human TR3 receptor: a member of steroid receptor superfamilyJ Steroid Biochem198934391395[PubMed][Google Scholar]
46. OhkuraNItoMTsukadaTSasakiKYamaguchiKMikiKStructure, mapping and expression of a human NOR-1 gene, the third member of the Nur77/NGFI-B familyBiochim Biophys Acta19961308205214[PubMed][Google Scholar]
47. OhkuraNHijikuroMYamamotoAMikiKMolecular cloning of a novel thyroid/steroid receptor superfamily gene from cultured rat neuronal cellsBiochem Biophys Res Commun199420519591965[PubMed][Google Scholar]
48. BookoutALJeongYDownesMYuRTEvansRMMangelsdorfDJAnatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional networkCell2006126789799[PubMed][Google Scholar]
49. LimRWYangWLYuHSignal-transduction-pathway-specific desensitization of expression of orphan nuclear receptor TIS1Biochem J1995308Pt 3785789[PubMed][Google Scholar]
50. OhkuraNItoMTsukadaTSasakiKYamaguchiKMikiKAlternative splicing generates isoforms of human neuron-derived orphan receptor-1 (NOR-1) mRNAGene19982117985[PubMed][Google Scholar]
51. MaltaisALabelleYStructure and expression of the mouse gene encoding the orphan nuclear receptor TECDNA Cell Biol200019121130[PubMed][Google Scholar]
52. PeiLWakiHVaitheesvaranBWilpitzDCKurlandIJTontonozPNR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolismNat Med20061210481055[PubMed][Google Scholar]
53. FormanBMChenJEvansRMHypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and deltaProc Natl Acad Sci U S A19979443124317[PubMed][Google Scholar]
54. GalmanCLundasenTKharitonenkovABinaHAErikssonMHafstromIDahlinMAmarkPAngelinBRudlingMThe circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in manCell Metab20088169174[PubMed][Google Scholar]
55. LehmannJMLenhardJMOliverBBRingoldGMKliewerSAPeroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugsJ Biol Chem199727234063410[PubMed][Google Scholar]
56. MoyersJSShiyanovaTLMehrbodFDunbarJDNoblittTWOttoKAReifel-MillerAKharitonenkovAMolecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signalingJ Cell Physiol200721016[PubMed][Google Scholar]
57. KharitonenkovADunbarJDBinaHABrightSMoyersJSZhangCDingLMicanovicRMehrbodSFKniermanMDHaleJECoskunTShanafeltABFGF-21/FGF-21 receptor interaction and activation is determined by betaKlothoJ Cell Physiol200821517[PubMed][Google Scholar]
58. LeeGHBhandaryBLeeEMParkJKJeongKSKimIKKimHRChaeHJThe roles of ER stress and P450 2E1 in CCl(4)-induced steatosisInt J Biochem Cell Biol20114314691482[PubMed][Google Scholar]
59. ZieglerDHanefeldMRuhnauKJMeissnerHPLobischMSchutteKGriesFATreatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study)Diabetologia19953814251433[PubMed][Google Scholar]
60. ZieglerDGriesFAAlpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathyDiabetes199746Suppl 2S62S66[PubMed][Google Scholar]
61. McCartyMFBarroso-ArandaJContrerasFThe "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alphaMed Hypotheses2009722933[PubMed][Google Scholar]
62. ParkKGMinAKKohEHKimHSKimMOParkHSKimYDYoonTSJangBKHwangJSKimJBChoiHSParkJYLeeIKLeeKUAlpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathwaysHepatology20084814771486[PubMed][Google Scholar]
63. KimHJKimJYLeeSJOhCJChoiYKLeeHJDoJYKimSYKwonTKChoiHSLeeMOParkISParkKGLeeKULeeIKAlpha-lipoic acid prevents neointimal hyperplasia via induction of p38 mitogen-activated protein kinase/Nur77-mediated apoptosis of vascular smooth muscle cells and accelerates postinjury reendothelializationArterioscler Thromb Vasc Biol20103021642172[PubMed][Google Scholar]